NCT03774355View on ClinicalTrials.gov

"Study to Compare Safety and Pharmacokinetics of CG1801 and CGL1802 in Healthy Volunteers"

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

May 3, 2019

Study Completion Date

May 3, 2019

Conditions
Healthy
Interventions
DRUG

CG1801

Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.

DRUG

CGL1802

Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

CrystalGenomics, Inc.

INDUSTRY